ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
☒ | Accelerated filer | ☐ | ||||
Non-accelerated filer | ☐ | Smaller reporting company | ||||
Emerging growth company |
PCAOB Auditor ID: |
Auditor Name: |
Auditor Location: |
Page |
||||||
Explanatory Note | ii | |||||
Corporate History and Background | ii | |||||
PART III |
||||||
Item 10. |
Directors, Executive Officers and Corporate Governance | 1 | ||||
Item 11. |
Executive Compensation | 13 | ||||
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 35 | ||||
Item 13. |
Certain Relationships and Related Transactions, and Director Independence | 37 | ||||
Item 14. |
Principal Accounting Fees and Services | 43 | ||||
PART IV |
||||||
Item 15. |
Exhibits, Financial Statement Schedules | 44 |
Name |
Age |
Position(s) (1) | ||||
Executive Officers |
||||||
Jagdeep Singh | 54 | President, Chief Executive Officer, Co-Founder and Chairman of the Board of Directors | ||||
Dr. Timothy Holme | 40 | Chief Technology Officer and Co-Founder | ||||
Dr. Mohit Singh | 43 | Chief Development Officer | ||||
Kevin Hettrich | 40 | Chief Financial Officer | ||||
Michael McCarthy | 56 | Chief Legal Officer and Head of Corporate Development | ||||
Celina Mikolajczak | 52 | Chief Manufacturing Officer | ||||
Non-Employee Directors |
||||||
Frank Blome | 53 | Director | ||||
Brad Buss (2)(3) | 58 | Director | ||||
Jeneanne Hanley | 49 | Director | ||||
Susan Huppertz | 52 | Director | ||||
Prof. Dr. Jürgen Leohold (3) | 67 | Director | ||||
Gena Lovett | 59 | Director | ||||
Justin Mirro (2)(4) | 53 | Director | ||||
Prof. Dr. Fritz Prinz | 72 | Director and Co-Founder | ||||
Dipender Saluja (2) | 57 | Director | ||||
JB Straubel | 46 | Director | ||||
Jens Wiese (4) | 49 | Director |
(1) | Each director and officer holds office until such person’s successor is elected and qualified or until such person’s earlier death, resignation or removal. |
(2) | Member of audit committee. |
(3) | Member of compensation committee. |
(4) | Member of nominating and corporate governance committee. |
Singh |
Blome |
Buss |
Hanley |
Huppertz |
Leohold |
Lovett |
Mirro |
Prinz |
Saluja |
Straubel |
Wiese |
|||||||||||||||||||||||||||||||||||||
Knowledge, Skills and Experience |
||||||||||||||||||||||||||||||||||||||||||||||||
Public company board experience and corporate governance |
● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||||
Executive experience |
● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||
Battery and energy technology |
● | ● | ● | ● | ● | ● | ||||||||||||||||||||||||||||||||||||||||||
Automotive industry |
● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||||||||||||||||||||||||||||||||||
Technology development |
● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||||
Manufacturing, scale-up, operations |
● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||||||||||||||||||||||||||||||||||
Financial |
● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||
Risk management |
● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||||||||||||||||||||||||||||||||||
HR, compensation |
● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||||
Demographics |
||||||||||||||||||||||||||||||||||||||||||||||||
Race/Ethnicity |
||||||||||||||||||||||||||||||||||||||||||||||||
Asian/Pacific Islander |
● | ● | ||||||||||||||||||||||||||||||||||||||||||||||
Black/African American |
● | |||||||||||||||||||||||||||||||||||||||||||||||
Caucasian |
● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||
Hispanic/Latino |
||||||||||||||||||||||||||||||||||||||||||||||||
Native American |
||||||||||||||||||||||||||||||||||||||||||||||||
Gender |
||||||||||||||||||||||||||||||||||||||||||||||||
Male |
● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||||||||||||||||||||||||||||||||||
Female |
● | ● | ● | |||||||||||||||||||||||||||||||||||||||||||||
Company Board Tenure |
||||||||||||||||||||||||||||||||||||||||||||||||
Years* |
12 | 2 | 2 | <1 | <1 | 7 | <1 | 2 | 11 | 10 | 2 | 1 |
* | Includes board service on both QuantumScape Corporation and Legacy QuantumScape, rounded to the nearest whole year |
• | selecting, compensating, and overseeing our independent registered public accounting firm; |
• | evaluating the performance, independence and qualifications of our independent registered public accounting firm and determining whether to retain our existing independent registered public accounting firm or engage a new independent registered public accounting firm; |
• | reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit and tax services; |
• | reviewing with the independent auditors and approving the annual audit plan, including the scope of audit activities and all critical accounting policies and practices to be used by us; |
• | reviewing our annual and quarterly financial statements and reports, including the disclosures in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and discussing the statements and reports with our independent auditors and management, and discussing with management and our independent registered public accounting firm the results of the annual audit and the quarterly reviews; |
• | reviewing our financial reporting processes, and disclosure controls and procedures; |
• | overseeing the design, implementation and performance of our internal audit function; |
• | reviewing and providing oversight of any related party transactions in accordance with our related party transaction policy and reviewing, monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics (the “Code of Conduct”); and |
• | establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting, auditing or other matters, including confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters. |
• | reviewing and approving the corporate goals and objectives that pertain to the determination of the compensation of our executive officers, including our chief executive officer; |
• | reviewing and approving performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; |
• | reviewing and approving or making recommendations to our board of directors regarding the compensation and other terms of employment of our executive officers, including our chief executive officer; |
• | reviewing and approving the terms of any employment agreements, severance arrangements, change in control arrangements and any other material arrangements for our executive officers; |
• | administering our equity incentive plans, to the extent such authority is delegated by our board of directors; reviewing, approving and administering our employee benefit and equity incentive plans; |
• | establishing and reviewing the compensation plans and programs of our employees, and ensuring that they are consistent with our general compensation strategy; |
• | making recommendations to our board of directors regarding the adoption or amendment of equity and cash incentive plans and approving amendments to such plans to the extent authorized by our board of directors; |
• | if the board of directors or committee establishes stock ownership guidelines for the executive officers and non-employee members of the board of directors, monitoring compliance with any such stock ownership guidelines; |
• | approving or making recommendations to our board of directors regarding the creation or revision of any clawback policy; |
• | reviewing and making recommendations to our board of directors regarding the type and amount of compensation to be paid or awarded to our outside board members; |
• | reviewing with management our disclosures under the caption “Compensation Discussion and Analysis” in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; |
• | preparing an annual report on executive compensation that the SEC requires in our annual proxy statement, to the extent such report is required; |
• | reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act; and |
• | reviewing and evaluating on an annual basis the performance of the compensation committee and recommending such changes as deemed necessary with our board of directors. |
• | reviewing and assessing and making recommendations to our board of directors regarding desired qualifications, expertise and characteristics sought of board members; |
• | identifying, reviewing and making recommendations of candidates to serve on our board of directors; |
• | considering our board of directors’ leadership structure, including the separation of the chairman and chief executive officer roles and/or appointment of a lead independent director of our board, either permanently or for specific purposes, and making such recommendations to our board of directors; |
• | developing and reviewing periodically policies and procedures for considering stockholder nominees for election to our board of directors and evaluating nominations by stockholders of candidates for election to our board of directors; |
• | evaluating the “independence” of directors and director nominees against the independence requirements of the NYSE, applicable rules and regulations of the SEC and other applicable laws; |
• | reviewing our succession planning process for our chief executive officer and any other members of our executive management team; |
• | evaluating the current size, composition and organization of our board of directors and its committees and making recommendations to our board of directors for approvals; |
• | recommending to our board of directors any changes to the corporate governance guidelines and corporate governance framework; |
• | reviewing issues and developments related to corporate governance and identifying and bringing to the attention of our board of directors current and emerging corporate governance trends; |
• | overseeing director orientation for new directors and continuing education for our directors; |
• | evaluating the performance of our board of directors and its committees and individual directors and determining whether continued service on our board of directors is appropriate; |
• | reviewing and monitoring compliance with our Code of Conduct, and reviewing possible, actual and potential conflicts of interest of our board members and officers other than related party transactions reviewed by our audit committee; |
• | administering policies and procedures for communications with the non-management members of our board of directors; |
• | if the board of directors or committee establishes stock ownership guidelines for the executive officers and non-employee members of the board of directors, monitoring compliance with any such stock ownership guidelines; and |
• | reviewing annually the nominating and corporate governance committee charter, structure and membership requirements and recommending any proposed changes to our board of directors, including undertaking an annual review of its own performance. |
• | Jagdeep Singh, our Chief Executive Officer (our “CEO”); |
• | Kevin Hettrich, our Chief Financial Officer; |
• | Dr. Tim Holme, our Chief Technology Officer; |
• | Celina Mikolajczak, our Chief Manufacturing Officer; and |
• | Dr. Mohit Singh, our Chief Development Officer. |
• | Reward talented executives, who possess proven experience, knowledge, skills, and leadership criteria; |
• | Motivate our executives by giving them a stake in our growth and prosperity and encouraging their continued service; and |
• | Align the interests of stockholders and named executive officers without creating an incentive for inappropriate risk-taking. |
• | Performance-Based Compensation |
• | Independent Compensation Committee |
• | Independent Compensation Consultant |
• | Annual Executive Compensation Review |
• | Minimal Perquisites and Special Benefits |
• | No “Golden Parachute” Tax Reimbursements “gross-ups”) on any tax liability that our executives might owe as a result of the application of Sections 280G or 4999 of the Internal Revenue Code (the “Code”). |
• | No Hedging and Pledging |
• | No “Single-Trigger” Change-in-Control change-in-control change-in-control change-in-control |
• | Clawback Arrangements. |
AMETEK | Lyft | |
Ballard Power Systems | Monolithic Power Systems | |
Cognex | Plug Power | |
Enphase Energy | Sunrun | |
First Solar | Teradyne | |
Keysight Technologies | Thor Industries | |
Lear | Trimble | |
Lumentum Holdings | Virgin Galactic Holdings |
• | Base salary; |
• | Annual incentive compensation paid in the form of cash bonuses; and |
• | Long-term incentive compensation in the form of performance option grants under our EPA Program. |
Name |
2021 Base Salary |
|||
Jagdeep Singh |
$ | 375,000 | ||
Kevin Hettrich |
$ | 375,000 | ||
Dr. Tim Holme |
$ | 375,000 | ||
Celina Mikolajczak(1) |
$ | 350,000 | (1) | |
Dr. Mohit Singh |
$ | 375,000 |
(1) | Ms. Mikolajczak joined as Vice President of Manufacturing Engineering in July 2021 and her actual base salary for 2021 was pro-rated for her actual period of employment. She was promoted to our Chief Manufacturing Officer in November 2021. Ms. Mikolajczak previously served as a member of our board of directors from April 2021 until resigning in May 2021 to accept her offer of employment. |
Name |
2021 Target Annual Incentive Opportunity |
|||
Jagdeep Singh |
$ | 125,000 | ||
Kevin Hettrich |
$ | 125,000 | ||
Dr. Tim Holme |
$ | 125,000 | ||
Celina Mikolajczak |
$ | 117,000 | ||
Dr. Mohit Singh |
$ | 125,000 |
Tranche |
Business Milestone Requirement |
Stock Price Target |
||||
1 | Achievement of 1 business milestone |
$ | 60 | |||
2 | Achievement of 2 business milestones (inclusive of the business milestone applicable to Tranche 1) |
$ | 120 | |||
3 | Achievement of 3 business milestones (inclusive of the business milestones applicable to Tranche 2) |
$ | 180 | |||
4 | Achievement of 4 business milestones (inclusive of the business milestones applicable to Tranche 3) |
$ | 240 | |||
5 | Achievement of 5 business milestones (inclusive of the business milestones applicable to Tranche 4) |
$ | 300 |
• | Delivery of an A-sample battery cell that meets specifications agreed upon with an automaker |
• | The validation by an auto maker of a completed B-sample battery cell (a B-sample battery cell is a functional, complete battery cell prototype produced from our pre-pilot or sample production line) |
• | Delivery of at least 1-gigawatt hour (GWh) of battery cells to a single customer |
• | Delivery of at least 3-gigawatt hour (GWh) of battery cells to each of three or more customers, with at least one of such customer being an auto maker |
• | $5 billion in GAAP revenue over a period of trailing four quarters |
• | $10 billion in GAAP revenue over a period of trailing four quarters |
• | Total cumulative battery cell production of 500 GWh |
• | Total cumulative battery cell production of 1,000 GWh |
• | Adjusted EBITDA margin of at least 25% over four consecutive quarters |
• | 10% of worldwide market share in automotive battery cells (excluding China) |
• | 20% of worldwide market share in automotive battery cells (excluding China) |
(1) | To permit flexibility in how the business develops, the production and market share targets include cells manufactured by the Company and its subsidiaries, joint ventures and licensees, and by cell makers who incorporate separators manufactured by or under license from the Company. |
• | Aligning our key service providers’ interests with those of the Company and our other stockholders; |
• | Motivating our key service providers to deliver sustainable and significant stockholder value through the achievement of ambitious performance milestones; |
• | Ensuring that the EPA Program is linked to performance and will not vest (and therefore not be of any value to recipient) unless all of our stockholders benefit from significant value creation; and |
• | Incentivizing our CEO and our other key service providers to continue to contribute to the Company over the long-term. |
Name |
Options Awarded under EPA Program |
|||
Jagdeep Singh |
8,399,133 | |||
Kevin Hettrich |
419,956 | |||
Dr. Tim Holme |
839,913 | |||
Celina Mikolajczak |
839,913 | |||
Dr. Mohit Singh |
839,913 |
* | Mr. Straubel was a member, and participated in the deliberations, of our compensation committee through 2021 and until February 16, 2022, but did not participate in the review and discussion with management of the Compensation Discussion and Analysis provided above. |
Name and principal position |
Year |
Salary ($) |
Bonus ($) |
Stock Awards ($) (1) |
Option Awards ($) (2) |
Non-equity Incentive Plan Compensation ($) (3) |
All Other Compensation ($) |
Total ($) |
||||||||||||||||||||||||
Jagdeep Singh |
2021 | 373,462 | — | — | 68,368,938 | 107,650 | 252,235 | (4) | 69,102,285 | |||||||||||||||||||||||
President, Chief Executive Officer and Director |
2020 | 277,116 | — | 16,719,999 | — | — | 55,000 | (5) | 17,052,115 | |||||||||||||||||||||||
2019 | 275,334 | — | — | — | — | — | 275,334 | |||||||||||||||||||||||||
Kevin Hettrich |
2021 | 373,506 | — | — | 3,418,434 | 107,596 | 21,120 | (6) | 3,920,656 | |||||||||||||||||||||||
Chief Financial Officer |
2020 | 310,096 | — | 3,344,000 | — | — | 63,000 | (5) | 3,717,096 | |||||||||||||||||||||||
2019 | 287,783 | — | 601,167 | — | — | — | 888,950 | |||||||||||||||||||||||||
Celina Mikolajczak |
2021 | 154,808 | — | 2,129,546 | (8) | 6,836,887 | 39,259 | 8,444 | (9) | 9,160,500 | ||||||||||||||||||||||
Chief Manufacturing Officer (7) |
2020 | — | — | — | — | — | — | — | ||||||||||||||||||||||||
2019 | — | — | — | — | — | — | — | |||||||||||||||||||||||||
Dr. Tim Holme, |
2021 | 373,716 | — | — | 6,836,887 | 107,734 | 252,259 | (4) | 7,570,596 | |||||||||||||||||||||||
Chief Technology Officer |
2020 | 285,683 | — | 1,672,000 | — | — | 58,300 | (5) | 2,015,983 | |||||||||||||||||||||||
2019 | 275,131 | — | — | — | — | — | 275,131 | |||||||||||||||||||||||||
Dr. Mohit Singh, |
2021 | 382,096 | — | — | 6,836,887 | 109,326 | — | 7,328,309 | ||||||||||||||||||||||||
Chief Development Officer |
2020 | 361,779 | — | 1,672,000 | — | — | 73,500 | (5) | 2,107,279 | |||||||||||||||||||||||
2019 | 350,136 | — | — | 905,627 | — | — | 1,255,763 |
(1) | The amounts in this column represent the aggregate grant-date fair value of awards granted to each named executive officer, computed in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. See Notes 2 and 10 to the audited consolidated financial statements in the Original Filing for a discussion of the assumptions made by us in determining the grant-date fair value of our equity awards. |
(2) | The amounts shown represent the aggregate grant date fair value of the option awards granted to each named executive officer computed in accordance with FASB ASC Topic 718. For 2021, the amounts reported relate to options under the EPA Program payable upon the five tranches described in the section titled “Equity Compensation—Extraordinary Performance Award Program” and are based upon the tranches currently probable to vest as of the grant date. These amounts do not correspond to the actual value that will be recognized by our named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in Notes 2 and 10 to the audited consolidated financial statements in the Original Filing. The grant date fair value of the options assuming achievement of the maximum level of performance (achievement of all five tranches) are, for Mr. Singh, $172,854,157; for Mr. Hettrich, $8,642,695; for Ms. Mikolajczak, $17,285,409; for Mr. Holme, $17,285,409; and for Dr. Singh, $17,285,409. |
(3) | These amounts reflect payments to these named executive officers pursuant to our 2021 Bonus Plan as described above in the section entitled “Compensation Discussion and Analysis—2021 Bonus Plan Design and Achievement. |
(4) | These amounts reflect HSR Act related payments made on behalf of Mr. Singh and Dr. Holme (and related tax gross ups) as described above in the section titled “Compensation Discussion and Analysis—Perquisites”. The amounts shown are $125,000 for each of Mr. Singh and Dr. Holme, and an additional payment of $127,235 and $127,259, respectively. |
(5) | These amounts reflect payments made in order to secure such named executive officer’s execution of an employee lock-up agreement in connection with the Company’s entry into the Business Combination Agreement. |
(6) | This amount reflects the fair value of certain financial planning fringe benefit payment services provided to Mr. Hettrich. |
(7) | Ms. Mikolajczak joined as our Vice President of Manufacturing Engineering in July 2021 and was promoted to Chief Manufacturing Officer in November 2021. Ms. Mikolajczak previously served as a member of our board of directors from April 2021 until resigning in May 2021 to accept her offer of employment. |
(8) | Amount includes an award of restricted stock units granted on April 13, 2021, with a grant-date fair value of $261,697. Upon Ms. Mikolajczak’s resignation from our board of directors, this award was automatically terminated and forfeited in full as no shares underlying this award had vested as of her resignation date. |
(9) | Amount represents outside director fees paid to Ms. Mikolajczak for her service as an outside director prior to her resignation. |
Name |
Grant Date |
Estimated Future Payments Under Equity Incentive Plan Awards |
All Other Stock Awards: Number of Shares of Stock or Units(2) |
All Other Option Awards: Number of Securities Subject to Options (#) |
Exercise or Base Price of Option Awards ($/Sh) |
Grant Date Fair Value of Stock and Option Awards (3) ($) |
||||||||||||||||||||||||||||||
Compensation Committee Approval Date |
Threshold (#) |
Target (#) |
Maximum (#) |
|||||||||||||||||||||||||||||||||
Jagdeep Singh |
12/16/2021 | (1) | 10/08/2021 | (1) | — | — | — | — | 8,399,133 | 23.04 | 172,854,157 | |||||||||||||||||||||||||
Kevin Hettrich |
12/16/2021 | (1) | 10/08/2021 | (1) | — | — | — | — | 419,956 | 23.04 | 8,642,695 | |||||||||||||||||||||||||
Celina Mikolajczak |
08/05/2021 | 08/05/2021 | — | — | — | 85,251 | — | 21.91 | 1,867,849 | |||||||||||||||||||||||||||
12/16/2021 | (1) | 10/08/2021 | (1) | — | — | — | — | 839,913 | 23.04 | 17,285,409 | ||||||||||||||||||||||||||
Dr. Timothy Holme |
12/16/2021 | (1) | 10/08/2021 | (1) | — | — | — | — | 839,913 | 23.04 | 17,285,409 | |||||||||||||||||||||||||
Dr. Mohit Singh |
12/16/2021 | (1) | 10/08/2021 | (1) | — | — | — | — | 839,913 | 23.04 | 17,285,409 |
(1) | These relate to the number of shares underlying the EPA Program stock option awards payable upon the achievement of the five tranches described in the section titled “—Equity Compensation—Extraordinary Performance Award Program” and based on the aggregate grant-date fair value of the awards computed in accordance with the FASB ASC Topic 718. Each of the five tranches vest only if we first achieve one of eleven specified business milestones, and then achieve the next applicable stock price target (i.e., $60, $120, $180, $240 and $300), within 10 years of the initial grants. In order to vest in any tranche, the participant generally must continue to provide service through the date of vesting in the same position, or a similar or higher role, as when the options under the EPA Program are granted. The EPA Program was designed to incentivize the achievement of ambitious long-term financial and operational objectives leading to large scale deployment of our battery technology, some of which would take many years, if at all, to be achieved. If any options have not vested by the end of the term of the option award, they will be forfeited and its recipients will not realize the value of such options. As of the date of this filing, none of the business milestones or stock price targets have been achieved, and consequently, no shares have vested under the EPA Program. Following vesting, the actual receipt of any shares by award recipients will further be subject to their payment of the exercise price of $23.04 per share. After our compensation committee approved the EPA Program awards on October 8, 2021, they were granted on December 16, 2021 following stockholder approval. Each named executive officer on this table received one EPA Program award grant in fiscal year 2021. See “—Equity Compensation—Extraordinary Performance Award Program” and “—Executive Compensation—Potential Payments upon Termination or Change in Control” for a further description of certain terms relating to these awards. |
(2) | Reflects awards of RSUs granted under the 2020 Equity Incentive Plan to Ms. Mikolajczak. 25% of the RSUs are scheduled to vest on our first quarterly vesting date following the one-year anniversary of August 15, 2021, and 6.25% of the RSUs are scheduled to vest each quarter thereafter, subject to Ms. Mikolajczak’s continuous service through each such date. See “—Executive Compensation—Potential Payments upon Termination or Change in Control” for a further description of certain terms relating to these awards. |
(3) | The amounts in this column represent the aggregate grant-date fair value of the award computed in accordance with the FASB ASC Topic 718. See Notes 2 and 10 to the audited consolidated financial statements in the Original Filing for a discussion of the assumptions made by us in determining the grant-date fair value of our equity awards. |
(4) | Represents an award of restricted stock units granted on April 13, 2021. Upon Ms. Mikolajczak’s resignation from our board of directors, this award was automatically terminated and forfeited in full as no shares underlying this award had vested as of her resignation date. |
Option Awards |
Stock Awards |
|||||||||||||||||||||||||||
Name |
Grant Date |
Number of Securities Underlying Unexercised Options Exercisable (#)(1)(2) |
Number of Securities Underlying Unexercised Options Unexercisable (#) |
Option Exercise Price ($) |
Option Expiration Date |
Number of Shares or Units of Stock That Have Not Vested (#) |
Market Value of Shares or Units of Stock That Have Not Vested ($)(3) |
|||||||||||||||||||||
Jagdeep Singh(4)(6) |
04/08/2013 | 2,010,874 | — | 0.64 | 04/08/2023 | — | — | |||||||||||||||||||||
Jagdeep Singh(5)(6) |
08/19/2016 | 2,499,520 | — | 1.31 | 08/19/2026 | — | — | |||||||||||||||||||||
Jagdeep Singh(6)(7) |
03/15/2017 | 6,498,753 | — | 1.33 | 03/15/2027 | — | — | |||||||||||||||||||||
Jagdeep Singh(6)(8) |
08/07/2020 | — | — | — | — | 2,764,950 | 61,354,241 | |||||||||||||||||||||
Jagdeep Singh(9) |
12/16/2021 | — | 8,399,133 | 23.04 | 12/16/2031 | — | — | |||||||||||||||||||||
Kevin Hettrich(6)(10) |
05/03/2016 | 265,680 | — | 1.31 | 05/03/2026 | — | — | |||||||||||||||||||||
Kevin Hettrich(6)(7) |
03/15/2017 | 467,551 | — | 1.33 | 03/15/2027 | — | — | |||||||||||||||||||||
Kevin Hettrich(6)(11) |
06/05/2019 | 251,360 | 150,814 | 2.38 | 06/05/2029 | — | — | |||||||||||||||||||||
Kevin Hettrich(6)(12) |
08/07/2020 | — | — | — | — | 469,206 | 10,411,681 | |||||||||||||||||||||
Kevin Hettrich(9) |
12/16/2021 | — | 419,956 | 23.04 | 12/16/2031 | — | — | |||||||||||||||||||||
Celina Mikolajczak(9) |
12/16/2021 | — | 839,913 | 23.04 | 12/16/2031 | — | — | |||||||||||||||||||||
Celina Mikolajczak(9)(13) |
08/05/2021 | — | — | — | — | 85,251 | 1,891,720 | |||||||||||||||||||||
Dr. Timothy Holme(4)(6) |
04/08/2013 | 333,804 | — | 0.64 | 04/08/2023 | — | — | |||||||||||||||||||||
Dr. Timothy Holme(14) |
02/27/2015 | 333,804 | — | 1.05 | 02/27/2025 | — | — | |||||||||||||||||||||
Dr. Timothy Holme(6)(7) |
03/15/2017 | 667,610 | — | 1.33 | 03/15/2027 | — | — | |||||||||||||||||||||
Dr. Timothy Holme(6)(12) |
08/07/2020 | — | — | — | — | 234,599 | 5,205,752 | |||||||||||||||||||||
Dr. Timothy Holme(9) |
12/16/2021 | — | 839,913 | 23.04 | 12/16/2031 | — | — | |||||||||||||||||||||
Dr. Mohit Singh(6)(15) |
06/17/2015 | 709,926 | — | 1.05 | 06/17/2025 | — | — | |||||||||||||||||||||
Dr. Mohit Singh(6)(7) |
03/15/2017 | 1,335,220 | — | 1.33 | 03/15/2027 | — | — | |||||||||||||||||||||
Dr. Mohit Singh(6)(11) |
06/05/2019 | 377,040 | 226,222 | 2.38 | 06/05/2029 | — | — | |||||||||||||||||||||
Dr. Mohit Singh(6)(12) |
08/07/2020 | — | — | — | — | 234,599 | 5,205,752 | |||||||||||||||||||||
Dr. Mohit Singh(9) |
12/16/2021 | — | 839,913 | 23.04 | 12/16/2031 | — | — |
(1) | All stock options that were granted prior to 2021 were granted pursuant to the 2010 Equity Incentive Plan. |
(2) | All stock options granted in 2021 were EPA Program awards and granted pursuant to the 2020 Equity Incentive Plan. |
(3) | The market value of unvested shares is calculated by multiplying the number of unvested shares held by the applicable named executive officer by the closing market price of our Class A Common Stock on the NYSE on December 31, 2021, which was $22.19 per share. |
(4) | 3/4th of these option shares vested on February 13, 2016, and the remainder were vested by February 13, 2017. |
(5) | These option shares vested by December 10, 2018. |
(6) | The equity award is eligible for accelerated vesting in the event the named executive officer’s employment is terminated in a qualifying termination in connection with a change in control. The acceleration rights are described below under “Executive Compensation—Potential Payments upon Termination or Change in Control.” |
(7) | These option shares vested as to 1/48th of the total shares subject to the option on May 1, 2017, and the remainder vested and will vest on each monthly anniversary thereafter, subject to the optionee’s continued service through each vesting date. |
(8) | 1/8th of the RSUs vested on February 15, 2021 and 1/16th vest quarterly thereafter, subject to the holder’s continued service through each vesting date. |
(9) | This EPA Program award vests based on attainment of certain performance conditions described in “Compensation Discussion and Analysis - Extraordinary Performance Award Program.” |
(10) | These option shares vested on April 27, 2019. |
(11) | These option shares vested as to 1/48th of the total shares subject to the option on July 5, 2019, and the remainder vested and will vest on each monthly anniversary thereafter, subject to the optionee’s continued service through each vesting date. |
(12) | 1/6th of the RSUs vested on February 15, 2021 and 1/12th vest quarterly thereafter, subject to the holder’s continued service as of each vesting date. |
(13) | 1/4th of the RSUs will vest on August 15, 2022 and 1/16th vest quarterly thereafter, subject to the holder’s continued service through each vesting date. |
(14) | These option shares vested on February 27, 2018. |
(12) | 1/4th of these option shares vested on June 17, 2016, and the remainder were vested by June 17, 2019. |
Option Awards |
Stock Awards |
|||||||||||||||
Name |
Number of Shares Acquired on Exercises (#) |
Value Realized on Exercise ($) |
Number of Shares Acquired on Vesting (#) |
Value Realized on Vesting ($) |
||||||||||||
Jagdeep Singh |
— | — | 1,256,800 | 47,896,648 | ||||||||||||
Kevin Hettrich |
— | — | 335,144 | 13,478,733 | ||||||||||||
Celina Mikolajczak |
— | — | — | — | ||||||||||||
Dr. Timothy Holme |
— | — | 167,576 | 6,386,401 | ||||||||||||
Dr. Mohit Singh |
1,642,794 | 42,333,207 | 167,576 | 6,739,660 |
• | continued base salary for 6 months, or 12 months for our CEO; |
• | up to 50% of each named executive officer’s potential bonus, in the discretion of our compensation committee; |
• | paid COBRA benefits for up to 6 months, or 12 months for our CEO; and |
• | no acceleration of equity awards. |
• | a lump-sum payment of 12 months of base salary; |
• | a lump-sum payment equal to 100% of the potential bonus; |
• | paid COBRA benefits for up to 12 months; and |
• | 100% acceleration of equity awards. |
• | $80,000 per year for service as a board member; |
• | $22,000 per year for service as lead independent director of our board of directors; |
• | $25,000 per year for service as chair of the audit committee; |
• | $12,500 per year for service as member of the audit committee; |
• | $18,000 per year for service as chair of the compensation committee; |
• | $9,000 per year for service as member of the compensation committee; |
• | $13,000 per year for service as chair of the nominating and corporate governance committee; and |
• | $6,500 per year for service as member of the nominating and corporate governance committee. |
Name(1) |
Fees Earned or Paid in Cash ($)(2) |
Stock Awards ($)(3) |
Option Awards ($) |
All Other Compensation ($) |
Total ($) |
|||||||||||||||
Frank Blome(4) |
— | — | — | — | — | |||||||||||||||
Brad Buss |
104,500 | 126,950 | — | — | 231,450 | |||||||||||||||
John Doerr(5) |
85,250 | 126,950 | — | — | 212,200 | |||||||||||||||
Jeneanne Hanley |
— | 441,471 | — | — | 441,471 | |||||||||||||||
Prof. Dr. Jürgen Leohold |
94,000 | 126,950 | — | — | 220,950 | |||||||||||||||
Celina Mikolajczak |
8,444 | (6) | 261,697 | (7) | — | — | 270,141 | |||||||||||||
Justin Mirro |
110,917 | 126,950 | — | — | 237,867 | |||||||||||||||
Dipender Saluja |
84,792 | 126,950 | — | — | 211,742 | |||||||||||||||
JB Straubel |
81,583 | 126,950 | — | — | 208,533 | |||||||||||||||
Jens Wiese(4) |
— | — | — | — | — |
(1) | Jagdeep Singh is a co-founder, executive officer and employee of the Company and therefore did not receive compensation in fiscal year 2021 as an outside director and is intentionally omitted from this table and the table below regarding outstanding equity awards. Prof. Dr. Fritz Prinz is a co-founder of the Company and even though he is a non-employee director, he received compensation in fiscal year 2021 in connection with certain technical consulting and advisory services provided to the Company, and therefore did not receive additional compensation as an outside director and is intentionally omitted from this table and the table below regarding outstanding equity awards. Each of Susan Huppertz and Gena Lovett joined our board of directors after December 31, 2021 and thus are intentionally omitted from this table and the table below regarding outstanding equity awards. |
(2) | Consists of board of directors and committee annual retainers and, if applicable, committee chair retainers. |
(3) | The amounts in this column represent the aggregate grant-date fair value of awards granted to each named executive officer, computed in accordance with the FASB’s ASC Topic 718. See Notes 2 and 10 to the audited consolidated financial statements included in the Original Filing for a discussion of the assumptions made by us in determining the grant-date fair value of our equity awards. |
(4) | Messrs. Blome and Wiese each waived their right to any compensation for their service as an outside director. |
(5) | Mr. Doerr retired from our board of directors in February 2022. |
(6) | This amount represents outside director fees paid to Ms. Mikolajczak for her service as an outside director prior to her resignation. Ms. Mikolajczak has retained such payments given they represented a pro rata payment for the period she served as an outside director. |
(7) | Upon Ms. Mikolajczak’s resignation from our board of directors, all such stock awards, none of which had vested, were automatically terminated and forfeited. |
Name |
Aggregate Number of Shares of Class A Common Stock Subject to Outstanding RSU Awards |
Aggregate Number of Shares Underlying Outstanding Options |
||||||
Frank Blome |
— | — | ||||||
Brad Buss |
5,294 | 1,407,612 | ||||||
John Doerr(1) |
5,294 | — | ||||||
Jeneanne Hanley |
19,070 | — | ||||||
Prof. Dr. Jürgen Leohold |
5,294 | 394,350 | ||||||
Celina Mikolajczak(2) |
— | — | ||||||
Justin Mirro |
5,294 | — | ||||||
Dipender Saluja |
5,294 | — | ||||||
JB Straubel |
5,294 | 1,005,437 | ||||||
Jens Wiese |
— | — |
(1) | Mr. Doerr retired from our board of directors in February 2022. |
(2) | Ms. Mikolajczak resigned in May 2021 to accept an employment offer from the Company and forfeited all of the RSUs that were formerly granted to her as an outside director. |
Plan Category |
(a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
(b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights(1) |
(c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) |
|||||||||
Equity compensation plans approved by stockholders(2) |
63,633,263 | $ | 7.74 | 32,114,587 | ||||||||
Equity compensation plans not approved by stockholders |
— | — | — | |||||||||
Total |
63,633,263 | $ | 7.74 | 32,114,587 |
(1) | The weighted average exercise price is calculated based solely on outstanding stock options. It does not take into account restricted stock units or shares issued under the ESPP, neither of which have any exercise price. |
(2) | Includes the following plans: the 2010 Plan, the 2020 Plan and the ESPP. Our 2020 Plan provides that on the first day of each fiscal year, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) 41,500,000 shares of Class A Common Stock, (ii) five percent (5%) of the aggregate number of shares of common stock outstanding on December 31st of the preceding fiscal year, or (iii) such other amount as may be determined by our board of directors. Our ESPP provides that on the first day of each fiscal year, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) 7,600,000 shares of Class A Common Stock, (ii) one percent (1%) of the aggregate number of shares of common stock outstanding on such date, or (iii) such other amount as may be determined by our board of directors. On January 1, 2021, the number of shares available for issuance under our 2020 Plan and our ESPP increased by 21,415,959 shares and 4,283,191 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above. |
• | The median of the total annual compensation of all employees (including temporary employees and interns and excluding Mr. Singh) of our Company was $145,391. |
• | Mr. Singh’s annual total compensation, as reported in the Summary Compensation Table included in this Amendment, was $69,102,285. As noted in the Summary Compensation Table, the vast majority of Mr. Singh’s 2021 annual total compensation reflects an accounting-driven valuation for his EPA Program stock option award, as to which no shares have vested as of the date of this filing, and which is further subject to the payment of an exercise price of $23.04 per share. |
• | Based on the above, for fiscal year 2021, the ratio of Mr. Singh’s total annual compensation to the median of the total annual compensation of all employees was 475 to 1. Excluding the effects of Mr. Singh’s EPA Program stock option award, none of which have vested, the ratio of Mr. Singh’s total annual compensation to the median of the total annual compensation of all employees was 5 to 1. |
• | We selected December 31, 2021, which is the last day of our fiscal year, as the date upon which we would identify the median employee. |
• | As of December 31, 2021, our employee population consisted of 580 individuals (including temporary employees and interns and excluding Mr. Singh). |
• | To identify the “median employee” from our employee population we used payroll records as of December 31, 2021. The compensation measure included the following: annualized base salary and target bonus that employees were eligible to earn during the year. |
• | With respect to the annual total compensation of the “median employee,” we identified and calculated the elements of such employee’s compensation for 2021 in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K, resulting in annual total compensation of $145,391. |
• | With respect to the annual total compensation for Mr. Singh, we used the amount reported in the “Total” column of our Summary Compensation Table included in this Amendment. |
• | each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; |
• | each of our named executive officers; |
• | each of our directors; and |
• | all of our executive officers and directors as a group. |
Shares Beneficially Owned |
||||||||||||||||||||||||||||
Class A Common Stock |
Class B Common Stock |
All Common Stock |
||||||||||||||||||||||||||
Name of Beneficial Owner |
Number |
% |
Number |
% |
Number |
% |
% of Total Vote+ |
|||||||||||||||||||||
Greater than 5% Stockholders: |
||||||||||||||||||||||||||||
Volkswagen Group of America Investments, LLC(1) |
68,236,103 | 20.38 | 17,980,436 | 18.87 | 86,216,539 | 20.05 | 19.27 | |||||||||||||||||||||
Khosla Ventures III, LP(2) |
1,286,463 | * | 30,609,901 | 32.13 | 31,896,364 | 7.42 | 23.88 | |||||||||||||||||||||
Capricorn Libra Investment Group, LP(3) |
17,991,722 | 5.37 | — | — | 17,991,722 | 4.18 | 1.40 | |||||||||||||||||||||
KPCB Holdings, Inc., as nominee(4) |
— | — | 5,070,532 | 5.32 | 5,070,532 | 1.18 | 3.94 | |||||||||||||||||||||
Named Executive Officers and Directors: |
||||||||||||||||||||||||||||
Jagdeep Singh(5) |
12,362,265 | 3.60 | 16,936,341 | 17.41 | 29,298,606 | 6.64 | 13.80 | |||||||||||||||||||||
Kevin Hettrich(6) |
1,039,209 | * | — | — | 1,039,209 | * | * | |||||||||||||||||||||
Dr. Timothy Holme(7) |
1,050,949 | * | 11,869,295 | 12.44 | 12,920,244 | 3.00 | 9.28 | |||||||||||||||||||||
Celina Mikolajczak |
— | — | — | — | — | — | — | |||||||||||||||||||||
Dr. Mohit Singh(8) |
2,481,068 | * | — | — | 2,481,068 | — | — | |||||||||||||||||||||
Frank Blome(9) |
— | — | — | — | — | — | — | |||||||||||||||||||||
Brad Buss(10) |
760,168 | * | — | — | 760,168 | — | — | |||||||||||||||||||||
Jeneanne Hanley |
— | — | — | — | — | — | — | |||||||||||||||||||||
Susan Huppertz |
— | — | — | — | — | — | — | |||||||||||||||||||||
Prof. Dr. Jürgen Leohold(11) |
273,541 | * | — | — | 273,541 | * | * | |||||||||||||||||||||
Gena Lovett |
— | — | — | — | — | — | — | |||||||||||||||||||||
Justin Mirro(12) |
1,734,056 | * | — | — | 1,734,056 | * | * | |||||||||||||||||||||
Prof. Dr. Fritz Prinz(13) |
833,200 | * | 11,484,541 | 12.06 | 12,317,741 | 2.86 | 8.98 | |||||||||||||||||||||
Dipender Saluja(14) |
2,744 | * | — | — | 2,744 | * | * | |||||||||||||||||||||
JB Straubel(15) |
871,382 | * | — | — | 871,382 | * | * | |||||||||||||||||||||
Jens Wiese(16) |
— | — | — | — | — | — | — | |||||||||||||||||||||
All directors and executive officers as a group (17 individuals)(17) |
23,410,050 | 6.67 | 40,290,177 | 41.34 | 63,700,227 | 14.20 | 32.15 |
* | Represents beneficial ownership of less than 1%. |
+ |
Shares of Class A Common Stock have one vote per share, while shares of Class B Common Stock have 10 votes per share. |
(1) | Consists of 68,236,103 shares of Class A Common Stock and 17,980,436 shares of Class B Common Stock. The business address of Volkswagen Group of America Investments, LLC (“VGA”) is 220 Ferdinand Porsche Dr. Herndon, VA 20171. |
(2) | Consists of 1,286,463 shares of Class A Common Stock and 30,609,901 shares of Class B Common Stock. The business address of Khosla Ventures III, LP is 2128 Sand Hill Road Menlo Park, CA 94025. |
(3) | Consists of 1,604,056 shares of Class A Common Stock held by Technology Impact Growth Fund, LP, 2,701,784 shares of Class A Common Stock held by TIGF Direct Strategies LLC – Series 3, 13,560,540 shares of Class A Common Stock held by Capricorn-Libra Investment Group, LP, and 125,342 shares of Class A Common Stock held by TIGF Partners, LLC. TIGF Partners, LLC is the general partner of Technology Impact Growth Fund, LP and the manager of TIGF Direct Strategies LLC - Series 3. TIGF Partners, LLC is owned by Dipender Saluja (40%), Ion Yadigaroglu (40%) and Capricorn Investment Group, LLC (20%). The business address of each of these entities is 250 University Avenue Palo Alto, CA 94301. |
(4) | Consists of 5,070,532 shares of Class B Common Stock. The business address of KPCB Holdings, Inc., as nominee is 2750 Sand Hill Road, Menlo Park, CA 94025. |
(5) | Consists of (a) options to purchase 8,998,273 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022, (b) options to purchase 2,010,874 shares of Class B Common Stock that are exercisable within 60 days of March 1, 2022, (c) 707,529 shares of Class A Common Stock held by Mr. Singh, (d) 1,340,582 shares of Class B Common Stock held by Mr. Singh, (e) 3,517,105 shares of Class B Common Stock held in trust by Jagdeep Singh, Trustee of the Roshni Singh 2020 Annuity Trust A dated September 1, 2020, (f) 3,517,105 shares of Class B Common Stock held in trust by Jagdeep Singh, Trustee of the Jagdeep Singh 2020 Annuity Trust A dated September 1, 2020, (g) 970,877 shares of Class A Common Stock and 6,550,675 shares of Class B Common Stock held in trust by Jagdeep Singh & Roshni Singh, Trustees of the Singh Family Trust UDT dated October 3, 1996, (h) 561,862 shares of Class A Common Stock held in trust by Tejbir Singh Phool, Trustee of the Kismet Diya Singh 2013 Trust dated July 31, 2013, (i) 561,862 shares of Class A Common Stock held in trust by Tejbir Singh Phool, Trustee of the Nageena Singh 2013 Trust dated July 31, 2013, and (j) 561,862 shares of Class A Common Stock held in trust by Tejbir Singh Phool, Trustee of the Noor Deepika Singh 2013 Trust dated July 31, 2013. Mr. Singh shares voting and dispositive power and is the trustee of each of Jagdeep Singh, Trustee of the Roshni Singh 2020 Annuity Trust A dated September 1, 2020, Jagdeep Singh, Trustee of the Jagdeep Singh 2020 Annuity Trust A dated September 1, 2020, Jagdeep Singh & Roshni Singh, Trustees of the Singh Family Trust UDT dated October 3, 1996, Tejbir Singh Phool, Trustee of the Kismet Diya Singh 2013 Trust dated July 31, 2013, Tejbir Singh Phool, Trustee of the Nageena Singh 2013 Trust dated July 31, 2013 and Tejbir Singh Phool, Trustee of the Noor Deepika Singh 2013 Trust dated July 31, 2013. |
(6) | Consists of (a) options to purchase 1,000,972 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022 and (b) 38,237 shares of Class A Common Stock held by Mr. Hettrich. |
(7) | Consists of (a) options to purchase 1,001,414 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022, (b) options to purchase 183,292 shares of Class B Common Stock that are exercisable within 60 days of March 1, 2022 and (c) 49,535 shares of Class A Common Stock and 11,686,003 shares of Class B Common Stock held by Dr. Holme. |
(8) | Consists of (a) options to purchase 2,461,738 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022 and (b) 19,330 shares of Class A Common Stock held by Dr. Singh. |
(9) | Mr. Blome, a member of our board of directors, is Head of Volkswagen AG’s Battery Center of Excellence. Mr. Blome disclaims beneficial ownership of all shares held by VGA referred to in footnote (1) above. |
(10) | Consists of (a) options to purchase 445,742 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022 and (b) 314,426 shares of Class A Common Stock held by Mr. Buss. |
(11) | Consists of (a) options to purchase 126,246 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022 and (b) 147,295 shares of Class A Common Stock held by Prof. Dr. Leohold. |
(12) | Consists of (a) 1,234,056 shares of Class A Common Stock held by Kensington Capital Partners, LLC, (b) 250,000 shares of Class A Common Stock held by the Justin E. Mirro 2020 Qualified Annuity Trust under agreement dated June 27, 2020, and (c) 250,000 shares of Class A Common Stock held by the Kensington Capital Trust under an agreement dated June 27, 2020. Mr. Mirro is the managing member and sole owner of Kensington Capital Partners, LLC. Mr. Mirro is trustee of the Justin E. Mirro 2020 Qualified Annuity Trust under agreement dated June 27, 2020. Mr. Mirro disclaims any beneficial ownership of the shares held by the Justin E. Mirro 2020 Qualified Annuity Trust under agreement dated June 27, 2020 other than to the extent he may have a pecuniary interest therein, directly or indirectly. Mr. Mirro’s spouse serves as the trustee of the Kensington Capital Trust under agreement dated June 27, 2020. Mr. Mirro disclaims any beneficial ownership of the shares held by the Kensington Capital Trust under agreement dated June 27, 2020 other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
(13) | Consists of (a) 519,920 shares of Class A Common Stock and 7,193,115 shares of Class B Common Stock held in trust by Friedrich Prinz and Gertrud Prinz, Trustees of The Prinz Family Trust dated September 17, 2018, (b) 156,640 shares of Class A Common Stock and 1,090,582 shares of Class B Common Stock held in trust by The Goldman Sachs Trust Company of Delaware, Trustee of the Marie Helene Prinz 2019 Trust dated June 17, 2019, (c) 156,640 shares of Class A Common Stock and 1,090,582 shares of Class B Common Stock held in trust by The Goldman Sachs Trust Company of Delaware, Trustee of the Benedikt F. Prinz 2019 Trust dated June 17, 2019, (d) 1,055,131 shares of Class B Common Stock held in trust by Friedrich Prinz, Trustee of the Gertrude Prinz Annuity Trust dated August 31, 2020, and (e) 1,055,131 shares of Class B Common Stock held in trust by Friedrich Prinz, Trustee of the Friedrich Prinz Annuity Trust dated August 31, 2020. Prof. Dr. Prinz shares voting and dispositive power and is the trustee of each of Friedrich Prinz and Gertrud Prinz, Trustees of The Prinz Family Trust dated September 17, 2018, Friedrich Prinz, Trustee of the Friedrich Prinz Annuity Trust dated August 31, 2020, Friedrich Prinz, Trustee of the Gertrude Prinz Annuity Trust dated August 31, 2020, The Goldman Sachs Trust Company of Delaware, Trustee of the Benedikt F. Prinz 2019 Trust dated June 17, 2019 and The Goldman Sachs Trust Company of Delaware, Trustee of the Marie Helene Prinz 2019 Trust dated June 17, 2019. |
(14) | Consists of 2,744 shares of Class A Common Stock held by Mr. Saluja. Mr. Saluja, a member of our board of directors, is Managing Director of Capricorn-Libra Investment Group, LP. Mr. Saluja disclaims beneficial ownership of all shares held by Capricorn-Libra Investment Group, LP referred to in footnote (3) above. |
(15) | Consists of (a) options to purchase 469,208 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022 and (b) 402,174 shares of Class A Common Stock held by Mr. Straubel. |
(16) | Mr. Wiese, a member of our board of directors, is Head of Volkswagen Group M&A, Investment Advisory, and Partnerships. Mr. Wiese disclaims beneficial ownership of all shares held by VGA referred to in footnote (1) above. |
(17) | Consists of (a) options to purchase 16,403,267 shares of Class A Common Stock that are exercisable within 60 days of March 1, 2022, (b) options to purchase 2,194,166 shares of Class B Common Stock that are exercisable within 60 days of March 1, 2022, (c) 7,006,783 shares of Class A Common Stock, and (d) 38,096,011 shares of Class B Common Stock. |
Item 13. |
Certain Relationships and Related Transactions, and Director Independence. |
• | we have been or are to be a participant; |
• | the amount involved exceeded or exceeds $120,000; and |
• | any of our directors (including director nominees), executive officers, or beneficial holders of more than 5% of any class of our voting securities, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for certain unlawful payments of dividends or redemptions or repurchases of shares; or |
• | for any breach of a director’s duty of loyalty. |
Stockholder |
Shares of Legacy QuantumScape Series F Preferred Stock |
Total Purchase Price Commitment |
||||||
Volkswagen Group of America Investments, LLC(1)(2) |
7,569,508 | $ | 200,000,026.48 | |||||
Al-Rayyan Holding LLC(3) |
3,557,668 | $ | 93,999,992.37 | |||||
2011 Buss Family Trust(3)(4) |
75,695 | $ | 1,999,998.16 | |||||
JB Straubel(3)(5) |
54,572 | $ | 1,441,890.47 | |||||
TIGF Direct Strategies LLC – Series 3(3)(6) |
870,493 | $ | 22,999,991.95 | |||||
Technology Impact Growth Fund, L.P.(3)(6) |
264,933 | $ | 7,000,006.74 | |||||
Quantum Partners LP(3)(7) |
722,363 | $ | 19,086,130.72 | |||||
Palindrome Master Fund LP(3)(7) |
101,921 | $ | 2,692,936.28 | |||||
JS Capital LLC(3)(7) |
824,284 | $ | 21,779,067.00 |
(1) | Frank Blome was a member of the board of directors of Legacy QuantumScape and is a member of our board of directors and an affiliate of VGA. Jens Wiese is a member of our board of directors and an affiliate of VGA. |
(2) | Includes shares that were purchased after the Business Combination on December 1, 2020 and shares that were purchased pursuant to the Series F Closing Agreement. |
(3) | All such were purchased on or prior to the Business Combination. |
(4) | Brad Buss was a member of the board of directors of Legacy QuantumScape and is a member of our board of directors and an affiliate of the 2011 Buss Family Trust. |
(5) | JB Straubel was a member of the board of directors of Legacy QuantumScape and is a member of our board of directors. |
(6) | Dipender Saluja was a member of the board of directors of Legacy QuantumScape and is a member of our board of directors and an affiliate of TIGF Direct Strategies LLC – Series 3 and Technology Impact Growth Fund, L.P. |
(7) | Affiliate of Soros Fund. |
2021 |
2020 |
|||||||
Audit Fees(1) |
$ | 2,106 | $ | 2,559 | ||||
Audit-Related Fees(2) |
— | 17 | ||||||
Tax Fees(3) |
176 | 23 | ||||||
|
|
|
|
|||||
Total Fees |
$ | 2,282 | $ | 2,599 |
(1) | “Audit Fees” consist of fees billed for professional services rendered in connection with the audit of our consolidated financial statements, reviews of our quarterly consolidated financial statements and related accounting consultations and services that are normally provided by the independent registered public accountants in connection with statutory and regulatory filings or engagements for those fiscal years. This category also includes fees for services incurred in connection with the Business Combination. |
(2) | “Audit-Related Fees” consists of fees for services for an information security assessment (the Trust Information Security Assessment Exchange, or TISAX). |
(3) | “Tax Fees” consists of fees for tax compliance services, including assistance with the preparation of income tax returns and general tax planning and consulting. |
(1) | Financial Statements: see Index to Consolidated Financial Statements appearing on page 50 of the Original Filing. |
(2) | Financial Statement Schedules. None. |
(3) | The exhibits listed below are filed as part of this Amendment or are incorporated herein by reference, in each case as indicated below. |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* | Filed herewith. |
# | Portions of this exhibit have been omitted in accordance with Item 601 of Regulation S-K. |
+ | Indicates a management or compensatory plan. |
QuantumScape Corporation | ||||||
Date: April 6, 2022 |
By: |
/s/ Jagdeep Singh | ||||
Jagdeep Singh | ||||||
Chief Executive Officer (Principal Executive Officer) |